SCHEMBL6737757

SCHEMBL6737757

O=C(O)[C@@H](CCc1ccccc1)NS(=O)(=O)Cc1ccc2sccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP7 P09237 1/20 0.46
MME P08473 1/20 0.41
ITGB3 P05106 4/20 0.40
ITGA2B P08514 2/20 0.40
ITGAV P06756 2/20 0.40
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
CTNNB1 P35222 1/20 0.39
WNT3A P56704 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ACE P12821 1/20 0.38
F10 P00742 1/20 0.38
CYP2A6 P11509 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6738805 1.00 MMP7 (0.46) MMP7MMEITGB3ITGA2BITGAV
SCHEMBL6738691 0.91 MMP2 (0.40) MMP7CTNNB1WNT3AALDH1A1KDM4E
SCHEMBL6737622 0.91 MMP2 (0.40) MMP7CTNNB1WNT3AALDH1A1KDM4E
SCHEMBL6841965 0.84 MMP7 (0.48) MMP7MMEITGB3ITGA2BITGAV
SCHEMBL6841969 0.84 MMP7 (0.48) MMP7MMEITGB3ITGA2BITGAV
SCHEMBL6741909 0.81 CTNNB1 (0.41) SLC1A3SLC1A2SLC1A1CTNNB1WNT3A
SCHEMBL1329533 0.81 SLC1A3 (0.56) MMP7MMEITGB3ITGA2BITGAV
SCHEMBL7061407 0.81 ITGAV (0.37) MMEITGB3ITGA2BITGAVSLC1A3
SCHEMBL7061415 0.81 ITGAV (0.37) MMEITGB3ITGA2BITGAVSLC1A3
SCHEMBL6742980 0.80 HDAC1 (0.40) MMP7ITGB3ITGA2BSLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates SMITHKLINE BEECHAM P.L.C. 2004-11-11 US disclosed
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2003-10-23 US disclosed
EP-1244616-A1 (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SmithKline Beecham plc (GB) 2002-10-02 EP disclosed
WO-2001047874-A1 (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES SMITHKLINE BEECHAM P.L.C. (GB) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199571-A1 (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives CD40, CD22, CD2 MMP7 1261/4885MME 1707/4885ITGB3 38/4885
US-20040225006-A1 (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates CD40, TNFRSF1A, CD2 MMP7 1581/4885MME 2152/4885ITGB3 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.